Radhakrishua Pillai

Title: Radhakrishua Pillai: Innovator in Selectin-Mediated Therapeutics

Introduction

Radhakrishua Pillai is a notable inventor based in Cranbury, NJ (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that can aid in diagnosing and treating selectin-mediated disorders.

Latest Patents

Radhakrishua Pillai holds a patent for "Linkable sialyl Lewis X analogs." This patent discloses a class of linkable tetrasaccharide compounds, including the amino phenyl glycoside of sialyl Lewis X (SLe) and related analogs. These compounds possess conjugatable nucleophilic groups, making them valuable for preparing multimeric SLe compositions. The SLe compounds can be utilized to create selectin binding ligand conjugates by linking them to various reporter moieties, such as contrast agents, radiodiagnostic agents, or cytotoxic and chemotherapeutic agents. The compounds and conjugates exhibit binding to selectin that is comparable to native Sialyl Le, thus proving useful for diagnosing and treating selectin-mediated disorders and related conditions. Radhakrishua Pillai has 1 patent to his name.

Career Highlights

Radhakrishua Pillai is associated with Bracco International Bv, where he continues to work on innovative solutions in the field of biochemistry. His research focuses on the development of compounds that can significantly impact medical diagnostics and therapeutics.

Collaborations

Some of his notable coworkers include Ramachandran S Ranganathan and Kondareddiar Ramalingam. Their collaborative efforts contribute to advancing research in selectin-mediated therapies.

Conclusion

Radhakrishua Pillai is a distinguished inventor whose work in developing linkable sialyl Lewis X analogs has the potential to transform the landscape of selectin-mediated disorder treatments. His contributions to the field are invaluable and continue to pave the way for future innovations.